RECIST 1.1 and serum thyroglobulin measurements in the evaluation of responses to sorafenib in patients with radioactive iodinerefractory differentiated thyroid carcinoma

Author：        

Publisher： Spandidos Publications

ISSN： 1792-1074

Source： Oncology Letters, Vol.6, Iss.2, 2013-01, pp. : 480-486

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Serum Thyroglobulin as a Risk Factor for Thyroid Carcinoma

By Hrafnkelsson Jón   Tulinius Hrafn   Kjeld Matthías   Sigvaldason Helgi   Jónasson Jón G.  

Acta Oncologica, Vol. 39, Iss. 8, 2000-11 ,pp. : 973-977

Informa Healthcare

Access to resources Recommend Favorite

Thyroglobulin Measurement and Postablative Iodine-131 Total Body Scan After Total Thyroidectomy for Differentiated Thyroid Carcinoma in Patients with No Evidence of Disease

By Tenenbaum F.   Corone C.   Schlumberger M.   Parmentier C.  

European Journal of Cancer, Vol. 32, Iss. 7, 1996-06 ,pp. : 1262-1262

Elsevier

Access to resources Recommend Favorite

Oncologic Outcomes After Completion Thyroidectomy for Patients with Well-Differentiated Thyroid Carcinoma

By Untch Brian   Palmer Frank   Ganly Ian   Patel Snehal   Michael Tuttle R.   Shah Jatin   Shaha Ashok  

Annals of Surgical Oncology, Vol. 21, Iss. 4, 2014-04 ,pp. : 1374-1378

Springer Publishing Company

Access to resources Recommend Favorite

CCND1 gene polymorphic variants in patients with differentiated thyroid carcinoma

By  

Oncology Letters, Vol. 9, Iss. 1, 2015-01 ,pp. : 442-448

Spandidos Publications

Access to resources Recommend Favorite

Predictive factors of cytotoxic damage in radioactive iodine treatment of differentiated thyroid cancer patients

By                

Molecular and Clinical Oncology, Vol. 3, Iss. 3, 2015-01 ,pp. : 692-698

Science Publishers

Access to resources Recommend Favorite